Viral Vector Production (Research-Use) Market Report 2026

The viral vector production (research-use) market size has grown rapidly in recent years. It will grow from $1.77 billion in 2025 to $2.04 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to increasing investment in gene therapy research, expansion of academic and translational research programs, availability of advanced cell culture technologies, rising use of viral vectors in oncology studies, growth of contract research activities.

The viral vector production (research-use) market size is expected to see rapid growth in the next few years. It will grow to $3.56 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to increasing demand for next-generation gene delivery tools, rising adoption of automation in research laboratories, expansion of CRISPR and gene editing research, growing collaboration between academia and biopharma, increasing focus on reproducibility and standardization. Major trends in the forecast period include increasing adoption of scalable viral vector manufacturing platforms, rising demand for high-purity research-grade vectors, growing use of suspension cell culture systems, expansion of automated upstream and downstream processing, enhanced focus on vector characterization and quality control.

The increasing prevalence of genetic disorders is anticipated to drive expansion in the viral vector production (research-use) market. Genetic disorders are conditions or illnesses resulting from anomalies in an individual's DNA, which may be inherited from one or both parents or arise from novel mutations. This uptick in genetic disorders stems from older parental ages, which heighten the chances of mutations being transmitted to children. The escalating incidence of genetic disorders bolsters the viral vector production (research-use) market by fueling the need for sophisticated gene delivery systems to investigate disease pathways and explore therapeutic strategies. For instance, in November 2024, the Centers for Disease Control and Prevention (CDC), a U.S. government public health organization, reported that Trisomy 21 (Down syndrome) affects roughly 1 in 643 births, leading to about 5,713 cases each year, while Trisomy 18 impacts about 1 in 3,336 births, or around 1,101 annual cases. Thus, the growing incidence of genetic disorders is poised to accelerate growth in the viral vector production (research-use) market.

Major companies in the viral vector production market are prioritizing advanced solutions, like specialized cell culture media, to enhance transfection efficiency, boost viral vector yields, and maintain consistent quality for research purposes. Cell culture media serve as nutrient-rich formulations that support cell growth and maintenance outside their natural setting. They include key ingredients such as amino acids, vitamins, and growth factors tailored to particular cell types and uses. For example, in January 2023, FUJIFILM Irvine Scientific, a US-based life sciences firm, launched BalanCD HEK293 Viral Feed, the first chemically defined nutrient feed optimized for HEK293 suspension cultures in AAV viral vector production. This product seeks to greatly increase adeno-associated virus (AAV) yields, achieving up to a 67% gain in viral packaging efficiency over basal media. The feed suits scalable gene therapy and biotech processes, delivering reliable results across various formats and compatibility with diverse media systems.

In January 2024, Oxford Biomedica Plc, a UK-based gene and cell therapy firm, purchased ABL Europe for an undisclosed sum. Through this acquisition, Oxford Biomedica seeks to broaden its footprint in the European market and strengthen its contract development and manufacturing organization (CDMO) services, especially in viral vector production. ABL Europe, based in France, focuses on developing and manufacturing viral vectors.

Major companies operating in the viral vector production (research-use) market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Lonza Group AG, Sartorius AG, Charles River Laboratories International Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Curia Inc., AGC Biologics GmbH, SK pharmteco Inc., Oxford Biomedica Plc, Waisman Biomanufacturing, Voyager Therapeutics Inc., FinVector Oy, Batavia Biosciences BV., GENEZEN LABORATORIES, BioNTech IMFS GmbH, VGXI Inc., Tonix Pharmaceuticals, Cell and Gene Therapy Catapult, Mustang Bio Inc.

North America was the largest region in the virtual vector production (research-use) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector production (research-use) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vector production (research-use) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viral vector production (research-use) market by increasing costs of imported bioreactors, cell culture media, plasmids, filtration systems, and analytical instruments required for vector manufacturing and purification. Research laboratories and biopharmaceutical research centers in North America and Europe are most affected due to reliance on imported high-precision equipment and consumables, while Asia-Pacific faces higher costs for research infrastructure expansion. These tariffs are increasing operational expenses and lengthening procurement cycles for research institutions. However, they are also encouraging local sourcing of consumables, domestic manufacturing of laboratory equipment, and regional capacity building for research-grade vector production.

The viral vector production (research-use) market research report is one of a series of new reports that provides viral vector production (research-use) market statistics, including viral vector production (research-use) industry global market size, regional shares, competitors with a viral vector production (research-use) market share, detailed viral vector production (research-use) market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector production (research-use) industry. This viral vector production (research-use) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vector production for research purposes involves the lab-based creation of engineered viruses that effectively transport genetic material into target cells during experiments. These vectors get modified to become replication-incompetent and secure within controlled research settings. The workflow includes designing the vector, producing it in host cells, and purifying it to guarantee quality, safety, and efficacy for scientific applications.

The primary types of viral vector production for research purposes include adeno-associated virus (AAV), lentivirus, adenovirus, retrovirus, and others. Adeno-associated viruses are small viruses that deliver genetic material into cells; they belong to the Parvoviridae family and cannot replicate on their own, depending instead on helper viruses. Various production approaches encompass transient transfection, stable cell lines, viral packaging systems, and additional methods across workflows such as upstream processing and downstream processing. Key applications span gene therapy, vaccines, oncology, infectious diseases, and more, serving end-users like pharmaceutical and biopharmaceutical companies as well as research institutes.

The viral vector production (research-use) market consists of sales of baculovirus, herpes simplex virus (HSV), vaccinia virus, vesicular stomatitis virus (VSV), hybrid viral vectors, and measles virus vectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.